Latest News Releases From The Newsroom
LEQEMBI Breakthrough: FDA Approves Eisai and Biogen's Alzheimer's Therapy
July 07th, 2023
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more
Lockheed Martin Lands Lucrative Contracts Worth $136M+
July 07th, 2023
Lockheed Martin Corporation (NYSE: LMT) has secured two significant contracts with a combined value of $136,102,558. The first contract is a $122,706,700 cost-plus-fixed-fee modification to an existing contract. This modification focuses on critic. Read more
Cronos Group Gains Ground on Potential Transaction, Gorilla Technology Seals $270M+ 3Y-Deal
July 06th, 2023
Shares of Cronos Group Inc. (Nasdaq: CRON) experienced a surge of over 5% in the extended session after confirming receipt of several unsolicited indications of interest from third parties, signaling potential transactions involving Cronos and these . Read more
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
July 06th, 2023
Action Follows Confirmatory Trial to Verify Clinical Benefit Silver Spring, MD / CRWE PRESS RELEASE / July 06, 2023 - Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult p. Read more
Breaking: Levi Strauss Lowers Outlook, AbbVie Reveals EPS Impact
July 06th, 2023
Levi Strauss & Co. (NYSE: LEVI) has released its financial results for the second quarter of 2023. The company reported earnings per share (EPS) of $0.04, slightly exceeding the consensus estimate of $0.03. However, net revenues for the quarter were . Read more
Market Surge: Mullen Gains Momentum, Pfizer's Investment Fuels Caribou Biosciences
July 06th, 2023
Shares of Mullen Automotive, Inc. (Nasdaq: MULN) surged over 60% in pre-market trading after the company announced a $25 million stock buyback program authorized through December 31, 2023. Mullen believes that its stock is significantly undervalue. Read more
Momentum Shift: Q2 Deliveries Boost Polestar, Bullish View On Aptiv
July 06th, 2023
Polestar Automotive Holding UK PLC (Nasdaq: PSNY) has announced its global deliveries for the second quarter of 2023, with a remarkable 73% year-on-year increase in deliveries in June. The company achieved its best-ever second quarter, delivering app. Read more
Perion Network Sees Upbeat Q2 Revenue; FDA's FTD Boosts Kazia
July 06th, 2023
Perion Network Ltd. (Nasdaq: PERI) has released its preliminary results, revealing an anticipated second-quarter 2023 revenue of $176 million, marking a 20% year-over-year increase. This projection surpasses the consensus estimate of $169.88 million . Read more
Citigroup's Buy Ratings: Ducommun, Textron, and TransDigm
July 06th, 2023
Ducommun Incorporated (NYSE: DCO), a leading provider of engineering and manufacturing services for aerospace and defense industries, received coverage initiation from Citigroup with a Buy rating and a price target of $65. Based on Wednesday's clo. Read more
Breaking Updates: JetBlue, Spirit Airlines, Deckers Outdoor, and AMD in Focus
July 05th, 2023
JetBlue Airways Corporation (Nasdaq: JBLU) has decided to terminate its Northeast Alliance (NEA) with American Airlines following a court ruling. The company will now shift its focus to a proposed combination with Spirit Airlines, Inc. (NYSE: SAVE), . Read more
Want To Find Some News?
News By Industries
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login